DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Farooqui MZ, Valdez J, Martyr S. et al.
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.
Lancet Oncol 2015;
16: 169-176
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.